RNXT (RenovoRx) FCF Margin %: -658.79% (As of Mar. 2026)


RNXT RenovoRx Inc RNXT
31 GF Score
Price $0.93
! 2 Warning Signs
View Full Analysis

What is RenovoRx FCF Margin %?

RenovoRx RNXT -2.41% 31 FCF Margin % is -658.79% as of Mar. 2026. GuruFocus rates RNXT with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, RenovoRx ranks worse than 76.75% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. RenovoRx's Free Cash Flow for the three months ended in Mar. 2026 was $-3.71 Mil. RenovoRx's Revenue for the three months ended in Mar. 2026 was $0.56 Mil. Therefore, RenovoRx's FCF Margin % for the quarter that ended in Mar. 2026 was -658.79%.

As of today, RenovoRx's current FCF Yield % is -26.95%.

The historical rank and industry rank for RenovoRx's FCF Margin % or its related term are showing as below:

RNXT' s FCF Margin % Range Over the Past 10 Years
Min: -21248.84   Med: -11113.07   Max: -758.97
Current: -758.97

During the past 7 years, the highest FCF Margin % of RenovoRx was -758.97%. The lowest was -21248.84%. And the median was -11113.07%.

RNXT's FCF Margin % is ranked worse than
76.75% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs RNXT: -758.97

RenovoRx FCF Margin % Related Terms

RenovoRx FCF Margin % Historical Data

* Premium members only.

The historical data trend for RenovoRx's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RenovoRx FCF Margin % Chart

RenovoRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -21,248.84 -977.29

RenovoRx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,717.26 -545.50 -853.38 -1,268.91 -658.79

RNXT vs NNVC, KALA, PSTV: FCF Margin % Comparison

For the Biotechnology subindustry, RenovoRx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RenovoRx FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's FCF Margin % distribution charts can be found below:

* The bar in red indicates where RenovoRx's FCF Margin % falls into.


RNXT
31GF Score
RenovoRx Inc RNXT
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RenovoRx FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

RenovoRx's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-10.975/1.123
=-977.29 %

RenovoRx's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.709/0.563
=-658.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -658.79% mean?
RenovoRx (RNXT) has a FCF Margin % of -658.79% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on RenovoRx and its competitors. According to the industry distribution chart, RenovoRx ranks #736 out of 959 companies in the Biotechnology industry, placing it in the top 76.7%.
Is RenovoRx's FCF Margin % too high?
RenovoRx's current FCF Margin % is -658.79%. Based on the distribution chart, RenovoRx ranks #736 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RenovoRx has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does RenovoRx's FCF Margin % compare to NNVC and KALA?
According to the Biotechnology industry distribution chart, RenovoRx ranks #736 out of 959 companies for FCF Margin %. This places RenovoRx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on RenovoRx and its competitors. RenovoRx's current FCF Margin % is -658.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RenovoRx stock overvalued right now?
RenovoRx (RNXT) has a current FCF Margin % of -658.79%. The current FCF Margin % is -658.79%. RenovoRx's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For RenovoRx (RNXT), the current FCF Margin % is -658.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RenovoRx Business Description

Address 2570 West El Camino Real, Suite 320, Mountain View, CA, USA, 94040
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
31GF Score

Get the complete analysis for RNXT

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93
Price